← Back

Wire · operational-macro

FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at cancernetwork.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

Alembic Pharmaceuticals received final FDA approval for generic binimetinib tablets in 15-mg and 45-mg strengths, used with encorafenib to treat BRAF-mutant melanoma and NSCLC. The drug is therapeutically equivalent to Mektovi and the company gained 180 days of generic exclusivity for both strengths.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 16 Nov 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

You can now plan to offer cost-competitive binimetinib treatment in the US, as Alembic holds exclusive generic rights for 180 days. This opens an opportunity to challenge brand pricing in BRAF-mutant melanoma and NSCLC therapies.

◆ Coverage

2 sources · first reported 16 Nov 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalgeneric-drugscancer-treatmentbinimetinibBRAF-mutation